7Baggers
 Oric Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $15.00  MarketBeat Sat, 15 Nov 2025 16:24:38 GMT
 oric-944 shows promise in combination with arpis for mcrpc  Urology Times Fri, 14 Nov 2025 20:44:44 GMT
 HC Wainwright Raises Price Target for ORIC to $23.00 While Maint  GuruFocus Fri, 14 Nov 2025 19:42:09 GMT
 Decoding ORIC Pharmaceuticals Inc (ORIC): A Strategic SWOT Insig  GuruFocus Fri, 14 Nov 2025 05:26:15 GMT
 ORIC Pharmaceuticals Reports Q3 2025 Financial Results  TipRanks Fri, 14 Nov 2025 04:26:36 GMT
 ORIC Reports Promising Phase 1b Trial Results for Prostate Cance  GuruFocus Thu, 13 Nov 2025 23:08:04 GMT
 ORIC Advances Cancer Treatments with Phase 3 Trials in Sight  GuruFocus Thu, 13 Nov 2025 23:08:03 GMT
 Oric Pharmaceuticals reports Q3 EPS (33c), consensus (40c)  TipRanks Thu, 13 Nov 2025 22:22:12 GMT
 Oric Pharmaceuticals Reports Promising ORIC-944 Trial Results  TipRanks Thu, 13 Nov 2025 21:51:51 GMT
 ORIC Pharmaceuticals reports positive data for prostate cancer drug  Investing.com Thu, 13 Nov 2025 21:23:55 GMT
 ORIC® Pharmaceuticals Announces Completion of Dose  GlobeNewswire Thu, 13 Nov 2025 21:05:00 GMT
 Precision Trading with Oric Pharmaceuticals Inc. (ORIC) Risk Zones  news.stocktradersdaily.com Sat, 08 Nov 2025 02:02:02 GMT
 oric pharmaceuticals stock rises after publishing research on cancer drug by investing.com  Investing.com South Africa Fri, 07 Nov 2025 13:49:58 GMT
 oric pharmaceuticals reports promising data for lung cancer drug by investing.com  Investing.com Nigeria Fri, 07 Nov 2025 07:47:55 GMT
 ORIC Pharmaceuticals reports promising data for lung cancer drug  Investing.com Thu, 06 Nov 2025 08:00:00 GMT
 published on: 2025-11-06 00:51:43  newser.com Thu, 06 Nov 2025 06:51:43 GMT

ORIC Pharmaceuticals, Inc
(NASDAQ:ORIC) 

ORIC stock logo

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of ...

Full Time Employees: 60
CEO: Jacob M. Chacko  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends